Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs Tacrolimus in Pediatric Steroid-Sensitive Nephrotic Syndrome
NCT07049172Completed
- Sponsor
- Wuhan Women and Children's Health Care Center
- Start
- Jan 2021
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of rituximab in nephrotic syndrome (2 arms), sponsored by Wuhan Women and Children's Health Care Center. Primary endpoints: Total Effective Rate at 6 months and Recurrence Rate at 6 months. Started Jan 2021; status: completed.
02
Drugs
rituximab
03
Conditions
nephrotic syndrome
Beyond the preview
Go deeper on NCT07049172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07049172.